Core Viewpoint - The company, Gilead Sciences-B (01672), has experienced a decline of over 6% in its stock price, currently trading at 14.55 HKD, following the announcement of a share placement and recent financial results [1] Group 1: Share Placement - Gilead Sciences plans to place 52.4 million shares at a price of 16.45 HKD per share, representing a discount of approximately 9.9% from the previous closing price [1] - The net proceeds from the placement are expected to be 468 million HKD, with about 90% allocated for clinical trials related to subcutaneous and oral peptide candidates for obesity [1] - The controlling shareholder, Wu Jinzi, will sell 52.4 million shares at the same price before subscribing to 28.82 million new shares, resulting in a cash-out of 388 million HKD [1] - Following the transaction, Wu Jinzi's ownership will decrease from 62.21% to 58.03% [1] Group 2: Financial Performance - Gilead Sciences reported total revenue of 104 million RMB, reflecting a year-on-year increase of 111.4% [1] - The company's loss narrowed to 87.95 million RMB, compared to a loss of 130 million RMB in the same period last year [1] - Dongwu Securities noted that Gilead Sciences' pipeline is progressing smoothly and aligns with expectations, with clearer timelines for future clinical data disclosures [1] - The likelihood of successful product launches in the future has increased, with the potential for revenue contribution from the drug, Denifasita [1]
港股异动 | 歌礼制药-B(01672)再跌超6% 公司拟折价配股净筹4.68亿港元 控股股东套现近3.9亿港元